uitsluitend voor onderzoeksdoeleinden
Cat.Nr.: S1019
Chemische structuur
| Gerelateerde doelwitten | VEGFR FGFR PDGFR c-Met Src MEK CSF-1R HER2 FLT3 c-Kit |
|---|---|
| Overige EGFR Inhibitoren | Lazertinib (YH25448) Icotinib Hydrochloride Sunvozertinib AG-490 AG-1478 Genistein Rociletinib (CO-1686) Poziotinib (NOV120101, HM781-36B) WZ4002 PD153035 HCl |
| Cellijnen | Assaytype | Concentratie | Incubatietijd | Formulering | Activiteitsbeschrijving | PMID |
|---|---|---|---|---|---|---|
| human HCC827 cells | Proliferation assay | 72 h | Antiproliferative activity against human HCC827 cells harboring EGFR del E746-A750 mutant after 72 hrs by MTS assay, IC50=0.001 μM | |||
| A431 cells | Function assay | Inhibition of EGF-stimulated autophosphorylation of EGFR enzyme in A431 cells detected by immunoblotting, IC50=0.0074 μM | ||||
| MDA-MB 453 cells | Function assay | Inhibition of autophosphorylation of ERBB2 receptor kinase in MDA-MB 453 cells, IC50=0.009 μM | ||||
| human BT474 cells | Proliferation assay | 3 days | Antiproliferative activity against human BT474 cells overexpressing ERBb2 after 3 days by methylene blue staining, EC50=0.01 μM | |||
| mouse BAF3 cells | Function assay | Inhibition of Blk expressed in mouse BAF3 cells assessed as cytotoxicity, IC50=0.029 μM | ||||
| human HN5 cells | Proliferation assay | 3 days | Antiproliferative activity against human HN5 cells overexpressing EGFR after 3 days by methylene blue staining, EC50=0.05 μM | |||
| human NCI-H1975 cells | Proliferation assay | 72 h | Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M mutant after 72 hrs by MTS assay, IC50=0.064 μM | |||
| human A431 cells | Proliferation assay | 72 h | Antiproliferative activity against human A431 cells overexpressing EGFR after 72 hrs by MTS assay, IC50=0.15 μM | |||
| human A549 cells | Proliferation assay | 72 h | Antiproliferative activity against human A549 cells expressing wild type EGFR coexpressing k-Ras mutant after 72 hrs by MTS assay, IC50=1.59 μM | |||
| mouse BAF3 cells | Function assay | Inhibition of JAK3 expressed in mouse BAF3 cells assessed as cytotoxicity, IC50=2 μM | ||||
| human HL7702 cells | Proliferation assay | 72 h | Antiproliferative activity against human HL7702 cells expressing wilt type EGFR after 72 hrs by MTS assay, IC50=2.3 μM | |||
| human A431 cells | Function assay | 1 μM | 1 h | Irreversible inhibition of EGFR autophosphorylation in human A431 cells at 1 uM incubated for 1 hr followed by compound wash out measured 5 hrs post EGF addition by Western blotting analysis | ||
| human LNCaP cells | Function assay | 10 μM | 2 h | Inhibition of autophosphorylation of immunoprecipitated flag-tagged Bmx expressed in human LNCaP cells assessed as incorporation of [32P]ATP at 10 uM pretreated for 2 hrs before transfection by immunoblot analysis | ||
| NCI-H1975 cells | Growth inhibition assay | 48 h | Inhibition of EGFR L858R/T790M mutant in human NCI-H1975 cells assessed as growth inhibition after 48 hrs by MTT assay | |||
| Klik om meer experimentele gegevens over de cellijn te bekijken | ||||||
| Moleculair gewicht | 485.94 | Formule | C24H25ClFN5O3 |
Opslag (Vanaf de ontvangstdatum) | |
|---|---|---|---|---|---|
| CAS-nr. | 267243-28-7 | SDF downloaden | Opslag van stamoplossingen |
|
|
| Synoniemen | PD183805 | Smiles | C=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4 | ||
|
In vitro |
4-Methylpyridine : 100 mg/mL
DMSO
: Insoluble
Water : Insoluble |
|
In vivo |
|||||
Stap 1: Voer de onderstaande informatie in (Aanbevolen: Een extra dier voor het geval van verlies tijdens het experiment)
Stap 2: Voer de in vivo formulering in (Dit is alleen de calculator, geen formulering. Neem eerst contact met ons op als er geen in vivo formulering is in het gedeelte Oplosbaarheid.)
Berekeningsresultaten:
Werkconcentratie: mg/ml;
Methode voor het bereiden van DMSO-mastervloeistof: mg geneesmiddel vooraf opgelost in μL DMSO ( Concentratie mastervloeistof mg/mL, Neem eerst contact met ons op als de concentratie de DMSO-oplosbaarheid van de partij geneesmiddel overschrijdt. )
Methode voor het bereiden van in vivo formulering: Neem μL DMSO mastervloeistof, voeg vervolgens toeμL PEG300, mengen en helder maken, voeg vervolgens toeμL Tween 80, mengen en helder maken, voeg vervolgens toe μL ddH2O, mengen en helder maken.
Methode voor het bereiden van in vivo formulering: Neem μL DMSO mastervloeistof, voeg vervolgens toe μL Maïsolie, mengen en helder maken.
Opmerking: 1. Zorg ervoor dat de vloeistof helder is voordat u het volgende oplosmiddel toevoegt.
2. Zorg ervoor dat u het/de oplosmiddel(en) in de juiste volgorde toevoegt. U moet ervoor zorgen dat de verkregen oplossing, bij de vorige toevoeging, een heldere oplossing is voordat u verdergaat met het toevoegen van het volgende oplosmiddel. Fysische methoden zoals vortexen, echografie of een warmwaterbad kunnen worden gebruikt om het oplossen te bevorderen.
| Kenmerken |
First kinase inhibitor to show irreversible activity and to have entered clinical trials (serving as a template for further development).
|
|---|---|
| Targets/IC50/Ki |
EGFR
(Cell-free assay) 1.5 nM
ErbB2
(Cell-free assay) 9.0 nM
|
| In vitro |
Canertinib (CI-1033) shows excellent potency for irreversible inhibition of erbB2 autophosphorylation in MDA-MB 453 cells, and also demonstrates high permeability in Caco-2 cells. This compound alone significantly suppresses constitutively activated Akt and MAP kinase, and in combination inhibits Akt while preventing increased levels of MAPK phosphorylation. It stimulates p27 expression and p38 phosphorylation in MDA-MB-453 cells. CI-1033 is highly specific to the erbB receptor family and not sensitive to PGFR, FGFR or IR even at 50 μM. It shows high levels of inhibition in A431 cells expressing EGFR with IC50 of 7.4 nM, and suppresses heregulin-stimulated tyrosine phosphorylation of erbB2, erbB3 and erbB4 with IC50 of 5, 14 and 10 nM, respectively. The compound also inhibits expression of pp62c-fos in response to heregulin. It is predicted to modify Cys773 covalently within the ATP binding site of the HER2 kinase and enhances destruction of both mature and immature ErbB-2 molecules. This compound induces a significant decrease in measurable phosphorylation of tyrosine residues 845 and 1068 of EGFR, which are responsible for Src and Ras/MAPK signaling respectively. The corresponding residues of Her-2, tyrosine residues 877 and 1248 are dephosphorylated significantly by it at a concentration of 3 μM or higher. CI could block EGFR internalization and increase the rate of apoptosis in primary osteosarcoma cells in a titratable fashion. In addition, it inhibits the proliferation of TT, TE2, TE6 and TE10 cells significantly at 0.1 nM. |
| Kinase Assay |
Tyrosine Kinase Assays
|
|
Enzyme assays voor de bepaling van IC50 worden uitgevoerd in 96-well filterplaten in een totaal volume van 0,1 mL, bevattende 20 mM Hepes, pH 7,4, 50 mM natriumvanaadaat, 10 μM ATP bevattende 0,5 mCi [32P]ATP, 20 mg polyglutaminezuur/tyrosine, 10 ng EGFR tyrosine kinase, en geschikte verdunningen van Canertinib (CI-1033). Alle componenten behalve het ATP worden aan de put toegevoegd en de plaat wordt 10 min bij 25 °C geïncubeerd onder schudden. De reactie wordt gestart door toevoeging van [32P]ATP, en de plaat wordt nog eens 10 min bij 25 °C geïncubeerd. De reactie wordt beëindigd door toevoeging van 0,1 mL 20% trichloorazijnzuur (TCA). De plaat wordt minimaal 15 min bij 4 °C bewaard om het substraat te laten neerslaan. De putten worden vervolgens vijf keer gewassen met 0,2 mL 10% TCA en de 32P-incorporatie wordt bepaald met een Wallac β-plaatenteller.
|
|
| In vivo |
Canertinib (CI-1033) shows impressive activity against A431 xenografts in nude mice at 5 mg/kg of body weight. This compound (20 to 80 mg/kg/d) achieves a high degree of tumor regressions in H125 xenograft models. Its oral administration causes a marked inhibition of growth in TT, TE6 and TE10 xenografts in nude mice, without animal death and <10% weight loss. |
Referenties |
|
| Methoden | Biomarkers | Afbeeldingen | PMID |
|---|---|---|---|
| Western blot | pEGFR / EGFR / p-HER2 / HER2 / p-HER3 / HER3 / MUC4 p-FAK / FAK / p-AKT / AKT |
|
25686822 |
| Growth inhibition assay | Cell viability |
|
28638122 |
(gegevens van https://clinicaltrials.gov, bijgewerkt op 2024-05-22)
| NCT-nummer | Rekrutering | Aandoeningen | Sponsor/Medewerkers | Startdatum | Fasen |
|---|---|---|---|---|---|
| NCT00050830 | Completed | Lung Neoplasms |
Pfizer |
January 2003 | Phase 2 |
| NCT00174356 | Completed | Carcinoma Non-Small Cell Lung |
Pfizer |
December 2002 | Phase 1 |
| NCT00051051 | Completed | Breast Neoplasms |
Pfizer |
December 2002 | Phase 2 |
Vraag 1:
I would like to know which is the best option/solvent to dilute it for in vivo experiments. (I am treating mice at 30mg/mL of this compound.)
Antwoord:
It is a suspension in the formulation recommended (30% Propylene glycol, 5% Tween 80, 65% D5W) on our product page at 30mg/ml. It’s fine for oral gavage.